Semaglutide, the active ingredient in Ozempic, is a GLP-1 receptor agonist
Developed by Theratechnologies Inc., it underwent phase II trials in the mid-2000s for GH deficiency (GHD) and HIV lipodystrophy but was discontinued, with reported reasons including hypersensitivity reactions, including an anaphylaxis-like reaction in one trial participant Wong et al (2008) [Note: Abstract only
"The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the health-care system." This report by The Canadian Press was first published April 28, 2026
J Pediatr (2015) 166:1914
Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY (2018) L-carnitine and heart disease
The $36 average monthly PDP premium is more than 4 times higher than the $8 average monthly premium for drug coverage in MA-PDs (weighted by enrollment) (Figure 4)